Regionale Zitratantikoagulation

ZUSAMMENFASSUNG

Die regionale Zitratantikoagulation ist inzwischen zum oftmals bevorzugten Antikoagulationsverfahren in der chirurgischen und anästhesiologischen Intensivmedizin geworden. Dem Nachteil des höheren Aufwandes und der Bedenken wegen Nebenwirkungen stehen die Vorteile gegenüber, weniger Blutverlust zu erleiden, höhere Filterlaufzeiten und konsekutiv höhere Dialysedosen zu erreichen und auch blutungsgefährdete Patienten behandeln zu können. Für die intermittierenden Verfahren gibt es mittlerweile ebenfalls zahlreiche Protokolle, die jedoch als weniger validiert gelten können. Die Weiterentwicklung der Zitratantikoagulation verspricht auch vorteilhaft für den intermittierenden Dialysebereich und der Therapie chronischer Dialysepatienten zu sein.

• 1 Schmitz M, Heering PJ, Hutagalung R. et al. Treatment of acute renal failure in Germany: Analysis of current practice. Medizinische Klinik, Intensivmedizin und Notfallmedizin 2015; 110: 256-263
• 2 KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl 2012; 2: S1-S138
• 3 Morita Y, Johnson RW, Dorn RE. et al. Regional anticoagulation during hemodialysis using citrate. Am J Med Sci 1961; 242: 32-43
• 4 Mehta RL, McDonald BR, Aguilar MM. et al. Regional citrate anticoagulation for continuous arteriovenous hemodialysis in critically ill patients. Kidney Int 1990; 38: 976-981
• 5 Gattas DJ, Rajbhandari D, Bradford C. et al. A Randomized Controlled Trial of Regional Citrate Versus Regional Heparin Anticoagulation for Continuous Renal Replacement Therapy in Critically Ill Adults. Crit Care Med 2015; 43: 1622-1629
• 6 Kutsogiannis DJ, Gibney RT, Stollery D. et al. Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney Int 2005; 67: 2361-2367
• 7 Liu C, Mao Z, Kang H. et al. Regional citrate versus heparin anticoagulation for continuous renal replacement therapy in critically ill patients: a meta-analysis with trial sequential analysis of randomized controlled trials. Crit Care 2016; 20: 144
• 8 Nurmohamed SA, Vervloet MG, Girbes AR. et al. Continuous venovenous hemofiltration with or without predilution regional citrate anticoagulation: a prospective study. Blood purification 2007; 25: 316-323
• 9 Morabito S, Pistolesi V, Tritapepe L. et al. Regional citrate anticoagulation in cardiac surgery patients at high risk of bleeding: a continuous veno-venous hemofiltration protocol with a low concentration citrate solution. Crit Care 2012; 16: R111
• 10 Schilder L, Nurmohamed SA, ter Wee PM. et al. Citrate confers less filter-induced complement activation and neutrophil degranulation than heparin when used for anticoagulation during continuous venovenous haemofiltration in critically ill patients. BMC Nephrol 2014; 15: 19
• 11 Oudemans-van Straaten HM, Bosman RJ, Koopmans M. et al. Citrate anticoagulation for continuous venovenous hemofiltration. Crit Care Med 2009; 37: 545-552
• 12 Hetzel GR, Schmitz M, Wissing H. et al. Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: a prospective randomized multicentre trial. Nephrol Dial Transplant 2011; 26: 232-239
• 13 Schilder L, Nurmohamed SA, Bosch FH. et al. Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial. Crit Care 2014; 18: 472
• 14 Stucker F, Ponte B, Tataw J. et al. Efficacy and safety of citrate-based anticoagulation compared to heparin in patients with acute kidney injury requiring continuous renal replacement therapy: a randomized controlled trial. Crit Care 2015; 19: 91
• 15 Gradwohl-Matis I, Franzen M, Seelmaier C. et al. Renal replacement therapy with regional citrate anticoagulation as an effective method to treat hypercalcemic crisis. ASAIO J 2015; 61: 219-223
• 16 Link A, Klingele M, Speer T. et al. Total-to-ionized calcium ratio predicts mortality in continuous renal replacement therapy with citrate anticoagulation in critically ill patients. Crit Care 2012; 16: R97
• 17 Meier-Kriesche HU, Gitomer J, Finkel K, DuBose T. Increased total to ionized calcium ratio during continuous venovenous hemodialysis with regional citrate anticoagulation. Crit Care Med 2001; 29: 748-752
• 18 Nurmohamed SA, Jallah BP, Vervloet MG. et al. Continuous venovenous haemofiltration with citrate-buffered replacement solution is safe and efficacious in patients with a bleeding tendency: a prospective observational study. BMC Nephrol 2013; 14: 89
• 19 Durao MS, Monte JC, Batista MC. et al. The use of regional citrate anticoagulation for continuous venovenous hemodiafiltration in acute kidney injury. Crit Care Med 2008; 36: 3024-3029
• 20 Schultheiß C, Saugel B, Phillip V. et al. Continuous venovenous hemodialysis with regional citrate anticoagulation in patients with liver failure: a prospective observational study. Crit Care 2012; 16: R162
• 21 Slowinski T, Morgera S, Joannidis M. et al. Safety and efficacy of regional citrate anticoagulation in continuous venovenous hemodialysis in the presence of liver failure: the Liver Citrate Anticoagulation Threshold (L-CAT) observational study. Crit Care 2015; 19: 349
• 22 Morabito S, Pistolesi V, Tritapepe L, Fiaccadori E. Regional citrate anticoagulation for RRTs in critically ill patients with AKI. Clin J Am Soc Nephrol 2014; 9: 2173-2188
• 23 Chenouard A, Liet JM. Regional Citrate Anticoagulation: Beware of Recirculation Phenomenon. Ther Apher Dial 2017; 21: 206-207
• 24 Gubensek J, Buturovic-Ponikvar J, Ponikvar R. Regional citrate anticoagulation for single-needle hemodialysis: a prospective clinical study. Blood Purif 2007; 25: 454-456
• 25 Buturovic-Ponikvar J, Cerne S, Gubensek J, Ponikvar R. Regional citrate anticoagulation for hemodialysis: calcium-free vs. calcium containing dialysate - a randomized trial. Int J Artif Organs 2008; 31: 418-424
• 26 Stegmayr BG, Jonsson P, Mahmood D. A significant proportion of patients treated with citrate containing dialysate need additional anticoagulation. Int J Artif Organs 2013; 36: 1-6
• 27 Sands JJ, Kotanko P, Segal JH. et al. Effects of citrate acid concentrate (citrasate(R)) on heparin N requirements and hemodialysis adequacy: a multicenter, prospective noninferiority trial. Blood Purif 2012; 33: 199-204
• 28 Grundström G, Christensson A, Alquist M. et al. Replacement of acetate with citrate in dialysis fluid: a randomized clinical trial of short term safety and fluid biocompatibility. BMC Nephrol 2013; 14: 216
• 29 Monchi M, Berghmans D, Ledoux D. et al. Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Med 2004; 30: 260-265
• 30 Morgera S, Scholle C, Melzer C. et al. A simple, safe and effective citrate anticoagulation protocol for the genius dialysis system in acute renal failure. Nephron Clin Pract 2004; 98: c35-c40
• 31 Gubensek J, Buturovic-Ponikvar J, Skofic N, Ponikvar R. Regional citrate anticoagulation for intermittent predilution online hemofiltration. Ther Apher Dial 2009; 13: 306-309
• 32 Beige J, Kuhlmann U. Durchführung intermittierender Dialysen mit zitratbasierter regionaler Antikoagulation nach den Regeln des Medizinproduktegesetzes. Positionspapier der Deutschen Gesellschaft für Nephrologie. Nephrologe 2017; 12: 43-44